

Treatment of Medication-Related Osteonecrosis at Dental Implants Utilizing CO₂ (9.3 μm) Laser and Sticky Bone: A Case Series

Scott Froum^{1,2}, Stephen Kelleher^{2,3}, Paras Ahmad², Georgios E Romanos¹ and Nathan E Estrin^{4*}

¹Department of Periodontics, School of Dental Medicine, Stony Brook University, Stony Brook, New York, USA

²Private Practice, New York, USA

³Department of Periodontics, New York University, New York, USA

⁴The University of Iowa College of Dentistry and Dental Clinics, Iowa City, IA, USA

*Corresponding author

Nathan E Estrin, Department of Periodontology, University of Iowa, Iowa City, Iowa, USA.

Received: April 10, 2026; **Accepted:** April 17, 2026; **Published:** April 27, 2026

ABSTRACT

Introduction: Medication-related osteonecrosis of the jaw (MRONJ) is a significant challenge for clinicians with limited treatment options. In this case series, a CO₂ laser (9.3μm) was utilized in conjunction with platelet-rich fibrin (PRF) mixed with allograft to create sticky Bone.

Materials & Methods: Four consecutive patients with MRONJ at implant sites were treated at a private practice setting. The necrotic bone was removed, and the sites were irradiated with a CO₂ laser and ethylenediaminetetraacetate (EDTA). Platelet-rich fibrin (PRF) mixed with BioOss Collagen particulate to create sticky bone to graft in the defect sites and secured with a solid-PRF membrane. Herbal-based mouthrinses in place of chlorhexidine was utilized as a post-surgical rinse. Follow-up time for the cases ranged from 6 months to 7 years.

Results: All patients healed uneventfully without any post-operative complications. In one case, a new implant was placed without any post-operative complications with a 2-year follow-up.

Conclusion: This case series demonstrates successful outcomes of treating MRONJ at implant sites utilizing CO₂ laser to decontaminate the implant surface and sticky bone for regenerative therapy. Additional controlled clinical studies are necessary to validate this technique.

Keywords: Medication-Related Osteonecrosis of the Jaw, MRONJ, Platelet-Rich Fibrin

Introduction

Medication-related osteonecrosis of the jaw (MRONJ) remains a significant challenge for clinicians due to its complex etiology and limited treatment options, as well as an expanding list of contributing medications.¹ Originally termed bisphosphonate-related osteonecrosis of the jaw (BRONJ) by Marx in 2003 for its primary association with bisphosphonates in cancer and osteoporotic patients, the name change to MRONJ reflects the inclusion of other medications, such as angiogenesis inhibitors,

anti-rheumatics, and RANKL medications [1-3]. Concerningly, the introduction of new medications associated with MRONJ directly reflects a rapid increase in the prevalence of the disease [3].

Bisphosphonates possess anti-osteoclastic properties to prevent bone loss, and, similar to the other medications associated with MRONJ, also function as strong angiogenesis inhibitors, dramatically lowering tissue oxygenation [3-5]. While the intention in cancer patients is to reduce the amount of blood flow to the tumor, the decrease in oxygenation can promote the invasion of oral anaerobic bacteria, leading to infection

Citation: Scott Froum, Stephen Kelleher, Paras Ahmad, Georgios E Romanos, Nathan E Estrin. Treatment of Medication-Related Osteonecrosis at Dental Implants Utilizing CO₂ (9.3 μm) Laser and Sticky Bone: A Case Series. J Stoma Dent Res. 2026. 4(2): 1-7. DOI: doi.org/10.61440/JSDR.2026.v4.49

of the exposed necrotic bone characteristic of the disease [6]. Additionally, anti-resorptives and immune modulators interfere with immune-cell activation and cytokine signaling that are normally involved in inflammation resolution [7]. The American Association of Oral and Maxillofacial Surgeons (AAOMS) released a series of position papers starting in 2007 in response to the increasing caseload experienced in private practice [1,8-10]. Recent literature has suggested an association between MRONJ and dental implants, with reports of both MRONJ lesions triggered by implant surgery, and also dental implant presence alone triggering necrosis [11]. MRONJ lesions have even been reported to occur at dental implants that were placed prior to the patient beginning anti-resorptive medication [12]. A recent systematic review by Nisi et al [13], included 24 articles reporting on peri-implantitis-induced MRONJ (Pi-MRONJ) and 111 total patients with MRONJ occurrence, highlighting the potential for dental implant and peri-implantitis to trigger MRONJ lesions in susceptible patients.

Currently, treatment options for MRONJ are frequently conservative and include bone sequestrum excision, local debridement, and a combination of systemic antibiotic therapy and/or administration of anti-microbial rinses, with chlorhexidine being the most recommended by the AAOMS [1,8]. However, platelet-rich fibrin (PRF) is a 100% autologous second-generation platelet concentrate that has emerged as a valuable adjunct in various oral surgery procedures due to its angiogenic potential, wound-healing support, and analgesic properties [14,15]. It is well documented that PRF can aid in both the treatment and prevention of MRONJ lesions owing to its regenerative capabilities [16,17].

Laser irradiation has also been proposed as an adjunctive modality in MRONJ treatment due to its ability to remove bone, reduce bacterial burden, and provide biostimulatory effects [18]. Specifically, the CO₂ laser (9.3µm) is particularly useful for both hard and soft tissue removal, given its high affinity for absorption of water and shallow penetration depth [19,20]. Additionally, when treating peri-implantitis, CO₂ lasers (10.6µm) can be utilized without damaging the implant surface when proper parameters are utilized [21,22]. In-vitro, it was demonstrated that irradiation with CO₂ lasers increases the hydrophilicity of titanium surfaces [23]. Additionally, a case series by Romanos and Nentwig demonstrated successful regenerative treatment around 19 implants with peri-implantitis utilizing a CO₂ laser to decontaminate the implant surface [24]. While the majority of the existing literature supports the use of Er: YAG for treating MRONJ, very limited evidence exists documenting the use of CO₂ lasers, with only one case series for a similar indication in treating osteoradionecrosis [25,18,26].

Therefore, the purpose of this case series is to present four cases demonstrating the use of CO₂ laser irradiation combined with a regenerative approach using PRF mixed with xenograft. This case series aims to demonstrate the clinical feasibility of this combined protocol and provide practical insight into managing implant-associated MRONJ lesions.

Methods

Prior to the start of data collection, Institutional Review Board (IRB) Exemption was obtained for the retrospective chart analysis from Sterling IRB (ID: 15998-NEstrin). Four patients

with implant-associated MRONJ lesions were treated in a private practice setting by the same clinician (S.F). All four patients underwent surgical regenerative therapy in which a full-thickness flap was reflected after adequate local anesthesia to completely expose the MRONJ lesion. Any loose necrotic bone was removed with rongeurs, and the remaining necrotic bone was removed with a 9.3 µm CO₂ laser (Solea, Convergent Dental, Boston, MA, USA) at 13.9 W. After all necrotic bone was removed, the laser was utilized at 0.4 W for 2 minutes of biostimulation. If attempting to regenerate around the existing implant, 24% ethylenediaminetetraacetate (EDTA) was placed on the implant surface for 2 minutes, followed by copious irrigation with saline. For PRF preparation, blood was drawn in 10 mL tubes (two blue-top tubes and two red-top tubes) and centrifuged at 700 x g for eight minutes utilizing a horizontal centrifuge (Bio-PRF, Florida, USA). After centrifugation, the red top tubes were flattened for solid-PRF membranes and sticky bone was fabricated by mixing both solid and liquid PRF with 90% anorganic bovine bone/10 % collagen (ABBC; Bio-Oss Collagen®, Geistlich, Wolhusen, Switzerland). The sticky bone complex was then applied over the titanium implant and/or defect and secured with a solid-PRF membrane prior to suturing with 4-0 Vicryl in a single interrupted fashion. Postoperative care included Amoxicillin 500 mg TID for three days, analgesics as required, and a homeopathic oral care recovery kit (StellaLife, StellaLife Inc, IL) for post-operative recovery [27].

Patients were scheduled for follow-up visits at two weeks (for suture removal) and followed during hygiene appointments every 3 months. The four clinical cases are demonstrated in Figures 1-8. This case series has been reported in line with the PROCESS guideline [28].




Figure 1: A 71-year-old male on methotrexate for Crohn's disease treatment presented to the clinic with an MRONJ lesion occurring at implant site #20 (placed by a different surgeon). A) Clinical pre-operative photo demonstrating significant probing depth on the buccal aspect. B) Pre-operative radiograph. C) Post-operative clinical photo with lesion resolution. D) 7-year post-operative radiograph




Figure 2: Surgical photos of the same patient. A) Defect after removing the necrotic bone with a CO₂ laser (Solea, Convergent Dental, Boston, MA, USA) at 13.9W and 0.4W for 2 minutes of biostimulation. B) EDTA was applied to the implant surface for 2 minutes. C) Sticky bone utilizing PRF with 90% anorganic bovine bone/10% collagen (ABBC; Bio-Oss®, Geistlich, Switzerland) was applied to the defect and secured with D) Solid-PRF membrane before closure



Figure 4: A 62-year-old female on ibandronate sodium for post-menopausal osteoporosis presented with an MRONJ lesion affecting implants #28 and #30, as well as dentition #26-#27. Both #26 and #27 were root canal-treated before surgery by a local endodontist (Dr. Joseph Dibernardo). A) Full-thickness flap reflection revealing necrotic bone, which was sent for biopsy. B) Clinical representation 3-months post-surgery during which both implants were removed, and defects were grafted according to the protocol above. C) 3-year follow-up clinical photograph after ridge augmentation and new implant at site #28




Figure 3: A 45-year-old male on Denosumab for prostate cancer presented with an MRONJ lesion around implant #30 (placed by another surgeon). A) Clinical pre-operative photo demonstrating significant probing depth at implant site #30. B) Pre-operative radiograph. C) Post-operative clinical photograph with lesion resolution. D) 6-month post-operative radiograph





Figure 5: A) Pathology report diagnosing necrotic bone at implant site #28. B) Clinical photograph of removed implant #28 with necrotic bone




Figure 6: A) and B) represent pre-operative radiographs of MRONJ lesions affecting teeth #26, #27 and Implants #28 and #30. C) 3-year post-operative radiograph after a new implant at #28 was placed




Figure 7: A 65-year-old female on methotrexate for rheumatoid arthritis presented with an MRONJ lesion at implant site #19 (placed 2 years prior). A) Pre-operative clinical photograph. B) 2-year post-operative clinical photograph. C) Necrotic bone removed from the implant site at the time of surgery




Figure 8: A) Pre-operative radiograph. B) Intra-operative radiograph after removal of necrotic bone. C) 2-year post-operative radiograph

Results

In this case series, four consecutive clinical cases of MRONJ were successfully managed utilizing a combined protocol consisting of surgical debridement with a 9.3 μm -CO₂ laser with regenerative therapy utilizing sticky bone via PRF with ABBC. Two female and two male patients were treated with follow-up times ranging from 6 months to 7-years. Two cases included MRONJ lesions due to methotrexate, while the other two cases were associated with ibandronate sodium and denosumab. In three of the cases, successful peri-implant regeneration was completed, while in one severe case, 2 implants were removed before ridge augmentation and new implant placement. All cases demonstrated uneventful post-operative healing with no post-operative infection or recurrent lesions.

Discussion

This case series demonstrated the clinical feasibility of treating implant-associated MRONJ lesions using a combined approach of CO₂ laser irradiation in conjunction with ABBC-based sticky bone for a regenerative approach. While previous literature documents occurrences of both implant surgery-triggered MRONJ and implant presence-triggered MRONJ, all four cases included in this case series fell in the latter category, highlighting the plausibility that local inflammation at implant sites may serve as a trigger in susceptible patients [13].

Implant-associated MRONJ is uniquely challenging because these lesions often occur in systemically compromised patients with the usual challenges of treating peri-implantitis, including chronic inflammation and a contaminated implant surface [13]. As is the case with treating peri-implantitis, it is critical to decontaminate the implant surface before attempting regeneration for predictable outcomes [29,30]. While previous evidence exists regarding the use of erbium-doped: yttrium, aluminum, and garnet laser (Er:YAG) for treating MRONJ, the rationale for utilizing the 9.3 μm CO₂ laser for decontamination is due to its efficiency in both hard and soft tissue management, as well as its safety and shallow penetration depth [25,31]. In peri-implantitis applications, CO₂ lasers have been demonstrated to successfully decontaminate the implants without damage/alternating the titanium surface if proper settings are utilized [21,22]. A recent in-vitro study by Romanos et al [23]. demonstrated improved surface wettability/surface energy of rough titanium surfaces with CO₂ irradiation, which may support early blood clot stabilization and cellular adhesion conducive to peri-implant regeneration. Additionally, a recent case series including five clinical cases of osteoradionecrosis demonstrated encouraging results utilizing the CO₂ laser in sequestrectomy of these lesions, warranting investigation in MRONJ lesions [26].

A second major component of this protocol was the utilization of sticky bone, utilizing ABBC with PRF. The adjunctive use of PRF in regenerative procedures has been well-documented owing to its 100% autologous platelets aiding in angiogenesis and wound-healing support and has been investigated for both prevention and adjunctive treatment of MRONJ lesions [32]. Additionally, in a recent systematic review by Estrin et al [15]. Including 200 studies in medicine and dentistry, PRF use was consistently associated with significant reductions in pain, one of the major symptoms and characteristics of MRONJ lesions. Clinically, PRF has demonstrated the ability to support predictable soft

tissue closure, which is particularly relevant in MRONJ lesions in which achieving a stable, asymptomatic condition with soft tissue coverage is desired as an end-goal [33].

Regarding post-operative protocol, a novel homeopathic, herbal-based recovery kit (StellaLife®) was utilized in place of chlorhexidine (CHX) despite prior guideline-based recommendations by the AAOMS frequently recommending CHX for MRONJ management [1,8]. While CHX possesses powerful antimicrobial properties, its lack of selective cytotoxicity may be a major drawback, as numerous reports have shown its cytotoxicity towards our own cells in the oral cavity and have demonstrated an increased pro-inflammatory response [27,34,35]. In part due to its cytotoxic and pro-inflammatory properties, many countries have entirely banned the use of chlorhexidine as an oral rinse [36]. Due to the above mentioned issues, more natural herbal compounds are increasingly being utilized as potential therapeutic options. Specifically, a novel VEGA Oral Care Recovery Kit (StellaLife®, StellaLife Inc., Aventura, FL, USA) was utilized in this study due to its selective cytotoxicity and ability to decrease bacterial loads while improving wound healing [36-39]. While the use of StellaLife® in the management of MRONJ warrants further investigation, this case series demonstrated the successful utilization of StellaLife® over CHX in the management of MRONJ lesions. Future research with less heterogeneity is necessary, with emphasis on patient-reported outcomes to evaluate their effectiveness in the management of MRONJ lesions of all stages.

Several limitations of this study should be acknowledged. This report represents a small case series without a control group, with many treatment variables. Decontamination protocols included CO₂ and EDTA while utilizing PRF and ABBC for regeneration and StellaLife® as a post-surgical antimicrobial rinse. Further studies with larger cohorts and standardized treatment approaches and follow-up protocols are necessary to further evaluate the effects of each treatment approach in managing MRONJ lesions.

Despite the limitations, this case series significantly demonstrates a successful regenerative approach to treating MRONJ lesions, which often clinicians are hesitant to treat, fearing the lesion may not resolve or worsen. This case series successfully incorporated a CO₂ laser and PRF laser to regenerate around existing implants and augment the bone in preparation for implant replacement.

Conclusion

Within the limitations of this case series, implant-associated MRONJ lesions were managed successfully using a combined protocol consisting of surgical removal of necrotic bone, CO₂ laser-assisted debridement/decontamination, and regenerative reconstruction using PRF-based sticky bone secured with a solid-PRF membrane. All four cases demonstrated uneventful healing without postoperative infection or recurrent exposed bone during follow-up, ranging from 6 months to 7 years, including one severe case requiring implant removal followed by ridge augmentation and subsequent implant replacement. Although this report cannot isolate the contribution of any single component of therapy, these outcomes support the feasibility of integrating CO₂ laser (9.3 μm) decontamination with PRF-based regeneration in complex implant-associated MRONJ defects.

Additionally, StellaLife® was utilized as a postoperative rinse in place of chlorhexidine and was well tolerated by the patients. Further controlled clinical studies are necessary to evaluate this treatment modality in MRONJ management.

Author contributions

Conceptualization, NEE, GER, and NEE.; methodology, NEE, SF, and SK; formal analysis, NEE, and SF.; investigation, NEE, and SF.; resources, NEE, SK, and SF; writing—original draft preparation, NEE, PA, and SF.; writing—review and editing, NEE, SK, and PA; supervision, SF, GER; project administration, SF, and GER. All authors have read and agreed to the published version of the manuscript.

Funding

This research was not supported by any funding.

Conflict of Interest

The authors report no conflict of interest.

References

- Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, et al. American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the Jaws—2022 update. *Journal of oral and maxillofacial surgery* 2022. 80: 920-943.
- Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. *Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons* 2003. 61: 1115-1117.
- King R, Tanna N, Patel V. Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab—a review. *Oral surgery, oral medicine, oral pathology and oral radiology*. 2019. 127: 289-299.
- Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. *Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons*. 2014. 72: 1938-1956.
- Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. *Journal of oral and maxillofacial surgery*. 2004. 62: 527-534.
- De Ponte FS, Favalaro A, Siniscalchi EN, Centofanti A, Runci M, et al. Sarcoglycans and integrins in bisphosphonate treatment: immunohistochemical and scanning electron microscopy study. *Oncology reports*. 2013. 30: 2639-2646.
- Roato I, Mauceri R, Notaro V, Genova T, Fusco V, et al. Immune Dysfunction in Medication-Related Osteonecrosis of the Jaw. *International Journal of Molecular Sciences*. 2023. 24: 7948.
- Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update. *Journal of Oral and Maxillofacial Surgery* 2009. 67: 2-12.
- Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. *Journal of oral and maxillofacial surgery* 2014. 72: 1938-1956.
- American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. *J Oral Maxillofac Surg*. 2007. 65: 369-376.
- Giovannacci I, Meleti M, Manfredi M, Mortellaro C, Greco Lucchina A, et al. Medication-Related Osteonecrosis of the Jaw Around Dental Implants: Implant Surgery-Triggered or Implant Presence-Triggered Osteonecrosis? *Journal of Craniofacial Surgery*. 2016. 27: 697-701.
- Pogrel M, Ruggiero S. Previously successful dental implants can fail when patients commence anti-resorptive therapy—A case series. *International journal of oral and maxillofacial surgery*. 2018. 47: 220-222.
- Nisi M, Gennai S, Graziani F, Barone A, Izzetti R. Clinical and radiologic treatment outcomes of implant presence triggered-MRONJ: Systematic review of literature. *Oral Diseases*. 2024. 30: 5255-5267.
- Miron RJ, Estrin NE, Ahmad P, Farshidfar N, Fujioka-Kobayashi M, et al. Thirty Years of Autologous Platelet Concentrates: From Platelet-Rich Plasma to Platelet-Rich Fibrin. *Journal of Periodontal Research*. 2025.
- Estrin NE, Tran TB, Ahmad P, Farshidfar N, Romanos GE, et al. Analgesic effects of platelet-rich fibrin (PRF): A systematic review. *Periodontology*. 2000. 2025.
- Miranda M, Gianfreda F, Raffone C, Antonacci D, Pistilli V, et al. The Role of Platelet-Rich Fibrin (PRF) in the Prevention of Medication-Related Osteonecrosis of the Jaw (MRONJ). *BioMed Research International*. 2021. 2021: 4948139.
- Cano-Durán JA, Peña-Cardelles J-F, Ortega-Concepción D, Paredes-Rodríguez VM, García-Riart M, et al. The role of Leucocyte-rich and platelet-rich fibrin (L-PRF) in the treatment of the medication-related osteonecrosis of the jaws (MRONJ). *Journal of clinical and experimental dentistry*. 2017. 9: e1051.
- Momesso GAC, Lemos CAA, Santiago-Júnior JF, Faverani LP, Pellizzer EP. Laser surgery in management of medication-related osteonecrosis of the jaws: a meta-analysis. *Oral and maxillofacial surgery*. 2020. 24: 133-144.
- Tuncer I, özçakır tomruk C, Sencift K, Cöloğlu S. Comparison of Conventional Surgery and CO₂ Laser on Intraoral Soft Tissue Pathologies and Evaluation of the Collateral Thermal Damage. *Photomedicine and laser surgery*. 2009. 28: 75-79.
- Barone A, Covani U, Crespi R, Romanos GE. Root Surface Morphological Changes After Focused Versus Defocused CO₂ Laser Irradiation: A Scanning Electron Microscopy Analysis. *Journal of Periodontology*. 2002. 73: 370-373.
- Kreisler M, Götz H, Duschner H, d'Hoedt B. Effect of Nd: YAG, Ho: YAG, Er: YAG, CO₂, and GaAlAs Laser Irradiation on Surface Properties of Endosseous Dental Implants. *International Journal of Oral & Maxillofacial Implants*. 2002. 17.
- Romanos GE, Estrin NE. Laser applications in peri-implantitis therapy: A narrative review. *Journal of Dentistry*. 2025. 162: 106081.
- Romanos GE, Varma M. CO₂ Laser Irradiation Positively Affects the Surface Energy of Rough Titanium Surfaces. *International Journal of Oral & Maxillofacial Implants*. 2025. 40.

24. Romanos GE, Nentwig GH. Regenerative therapy of deep peri-implant infrabony defects after CO₂ laser implant surface decontamination. *Int J Periodontics Restorative Dent* 2008. 28: 245-255.
25. Angiero F, Sannino C, Borloni R, Crippa R, Benedicenti S, et al. Osteonecrosis of the jaws caused by bisphosphonates: evaluation of a new therapeutic approach using the Er: YAG laser. *Lasers in medical science*. 2009. 24: 849-856.
26. Qualliotine JR, Yousef A, Orosco RK, Fugere M, Kolb FJ, et al. Carbon Dioxide Laser Sequestrectomy for Osteoradionecrosis: A Case Series. *Photobiomodulation, photomedicine, and laser surgery*. 2023. 41: 73-79.
27. Estrin NE, Romanos GE, Tatch W, Pikos M, Miron RJ. Biological Characterization, Properties, and Clinical Use of a Novel Homeopathic Antiseptic Oral Recovery Kit: A Narrative Review. *Oral health & preventive dentistry*. 2022. 20: 485-499.
28. Agha RA, Sohrabi C, Mathew G, Franchi T, Kerwan A, et al. The PROCESS 2020 guideline: updating consensus preferred reporting of CasE series in surgery (PROCESS) guidelines. *International Journal of Surgery*. 2020. 84: 231-235.
29. Estrin NE, Suzuki JB, Bronstein D, Romanos G. Current Implant Maintenance Protocols and Their Significance. *Compendium of Continuing Education in Dentistry*. 2025. 46.
30. Koo K-T, Khoury F, Keeve PL, Schwarz F, Ramanauskaite A, et al. Implant surface decontamination by surgical treatment of periimplantitis: a literature review. *Implant dentistry*. 2019. 28: 173-176.
31. Romanos G. Current concepts in the use of lasers in periodontal and implant dentistry. *Journal of Indian Society of Periodontology*. 2015. 19: 490-494.
32. Miranda M, Gianfreda F, Raffone C, Antonacci D, Pistilli V, et al. The role of platelet-rich fibrin (PRF) in the prevention of medication-related osteonecrosis of the jaw (MRONJ). *BioMed Research International*. 2021. 2021: 4948139.
33. Miron RJ, Estrin NE, Ahmad P, Farshidfar N, Fujioka-Kobayashi M, et al. Thirty Years of Autologous Platelet Concentrates: From Platelet-Rich Plasma to Platelet-Rich Fibrin. *Journal of Periodontal Research*. 2025.
34. Sawada K, Fujioka-Kobayashi M, Kobayashi E, Schaller B, Miron RJ. Effects of antiseptic solutions commonly used in dentistry on bone viability, bone morphology, and release of growth factors. *Journal of oral and maxillofacial surgery*. 2016. 74: 247-254.
35. Sawada K, Nakahara K, Haga-Tsujimura M, Fujioka-Kobayashi M, Iizuka T, et al. Effect of irrigation time of antiseptic solutions on bone cell viability and growth factor release. *Journal of craniofacial surgery*. 2018. 29: 376-381.
36. Estrin NE, Moraschini V, Zhang Y, Romanos GE, Sculean A, et al. Combination of Nd: YAG and Er: YAG lasers in non-surgical periodontal therapy: a systematic review of randomized clinical studies. *Lasers in medical science*. 2022: 1-7.
37. Mueller M, Hobiger S, Jungbauer A. Anti-inflammatory activity of extracts from fruits, herbs and spices. *Food chemistry*. 2010. 122: 987-996.
38. Simsek G, Sari E, Kilic R, Bayar Muluk N. Topical application of arnica and mucopolysaccharide polysulfate attenuates periorbital edema and ecchymosis in open rhinoplasty: a randomized controlled clinical study. *Plastic and reconstructive surgery*. 2016. 137: 530e-535e.
39. Laugisch O, Ramseier CA, Salvi GE, Hägi TT, Bürgin W, et al. Effects of two different post-surgical protocols including either 0.05% chlorhexidine herbal extract or 0.1% chlorhexidine on post-surgical plaque control, early wound healing and patient acceptance following standard periodontal surgery and implant placement. *Clinical oral investigations*. 2016. 20: 2175-2183.